Loading company
XTL Biopharmaceuticals Ltd.
XTLB · Nasdaq · ·
$2.20-8.7%Sep 25 close
- 1M
- -10.9%
- 6M
- -15.7%
- 1Y
- -88.2%
- 5Y
- -96.7%
XTLB · Nasdaq · ·
$2.20-8.7%Sep 25 close
From the company’s own 6-K filing.
Biopharmaceuticals Ltd. (XTL) XTL is an IP portfolio company. The Company holds 100% of the share capital of The Social Proxy Ltd. (the “Social Proxy”), a web data company and has sublicensed out an IP portfolio surrounding hCDR1 for the treatment of Lupus disease (SLE). XTL is traded on the Nasdaq Capital Market (NASDAQ: XTLB) and the Tel Aviv Stock Exchange (TASE: XTLB.TA).
The company’s own description, as it appears at the foot of the release.
The quote and the company description come from the 6-K XTL Biopharmaceuticals Ltd. filed on December 30, 2025 with its results; the table is built from its quarterly reports. Read the release on EDGAR Share prices are split- and dividend-adjusted.
XTL Biopharmaceuticals Ltd. has no earnings call transcript available.